Avaliação da atividade antiinflamatória e toxicidade aguda e sub-crônica de análogos de talidomida contendo diaminas e estrutura ftalimídica aberta
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora
DOI
Abstract
Thalidomide exhibits anti-inflammatory and immunomodulatory effects,
improving clinical symptoms in a variety of diseases, including erythema
nodosum leprosum, Crohn disease, rheumatoid arthritis, cancer and other
vascular and inflammatory diseases. In previous study from our laboratory it has
been shown that thalidomide analogues containing diamines and open
phthalimide structure, showed high inhibitory in vitro activity on key molecules
such as TNF-a, IL-12, IFN-g, IL-6, CXCL9, CXCL10 and CD80. In contrast,
some compounds induced an increase in IL-10 production. In this study, the
anti-inflammatory activity of two thalidomide analogues (GI-16 and SC-15) were
evaluated in vivo using the carrageenan-induced paw inflammation on BALB/c
mouse and the LPS-induced lung inflammation in C57Bl/6 mice. In addition, the
acute and sub-chronic toxicity of the compounds on Wistar rats were evaluated.
The treatment with both GI-16 (10mg/kg and 50mg/kg) and SC-15 (50mg/kg)
reduced significantly (53-77%) the paw oedema over 24h evoked by subplantar
injection of 2% carrageenan. GI-16 (20mg/kg and 50mg/kg) and SC-15
(50mg/kg) greatly inhibited LPS-induced TNF-a (around 34%) and IL-6 (66-
89%) in lung homogenate. In contrast, thalidomide (50mg/kg) and SC-15
(50mg/kg) enhanced IL-10 (p<0,05). As expected, thalidomide and the
reference drug, dexamethasone, caused significant inhibition of both
carrageenan-induced oedema and of TNF-a and IL-6 production 24 h after
intratracheal administration of LPS (200ug/ml). Histopathological analysis has
shown that GI-16 treatment induced reduction in LPS–induced inflammation
characterized by discrete capillary congestion. In contrast, animals treated with
SC-15, showed moderate to intense inflammatory infiltrate, thickening of alveolar
wall and vascular congestion at 20mg/kg, and reduced inflammation at 50mg/kg.
Female and male Wistar rats administered with GI-16 and SC-15 (20mg/kg) did
not develop any clinical signs of acute toxicity (single dose) or sub-chronic
toxicity (every other day for 28 days) either immediately or during the posttreatment
period. No mortality occurred in both, control and treated animals
either immediately or during the treatment period. Body weight gain over time
10
was similar in all groups. There was not significant alteration in biochemical or
hematological parameters. Sections of heart, liver and kidneys tissues of the
studied rats showed no pathological alterations under light microscopy. These
results strongly reinforce the anti-inflammatory effects of GI-16 and SC-15,
which make them very attractive drug candidates to treat a broad range of
inflammatory diseases.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
